乌体林斯和黄芪注射液联用治疗缓解期哮喘的临床观察

Mycobacterium phlei F.U.36 combined with Huangqi injections for stable asthma

目的观察哮喘缓解期联用乌体林斯、黄芪注射液、鱼腥草注射液穴位注射控制哮喘发作的疗效，探讨其作用机理。方法哮喘缓解期患者56例，随机分成两组。治疗组32例采用相同穴位交替选择药物，隔日穴位注射治疗；对照组24例予常规治疗。并观察两组疗效及治疗前后用力肺活量（FVC），1秒钟用力呼气量（FEV1）和肺活量（VC）的变化。结果两组总有效率为96．87％和79．17％，治疗组优于对照组（χ^2=10，P〈0．01）。治疗组治疗前后肺功能明显改善，治疗前后比较VC分别为（1．79±0．43）L和（2．91±0．64）L，P〈0．05；FVC分别为（1．64±0．46）L和（2．09±0．62）L，P〈0．05；FEV1分别为（0．92±0．70）L和（1．35±0．35）L，P〈0．05。对照组治疗前后肺功能改善不明显（P均〉0．05）。治疗组明显优于对照组。结论在哮喘缓解期联用乌体林斯、黄芪注射液、鱼腥草注射液穴位注射控制哮喘发作的临床疗效优于常规治疗。

Objective To investigate the efficacy of acupoint injections of mycobacterium phlei F.U.36 combined with huangqi, and cordate houttuynia for stable. Methods 56 patients with stable asthma were randomized to receive acupoint injections of mycobacterium phlei F.U.36, huangqi, and cordate houttuynia every the other day （study group, 32 patients）, or conventional therapy （control group, 24 patients）. The efficacy was observed in the two groups. The changes in FVC, FEVI, and VC were determined. Results The study group was superior to the control group in the total effective rate （96.87% vs 79.17%; χ^2=10, P〈 0.01）. VC, FVC, and FEVI were markedly improved in the study group （[2.91 ± 0.64] vs [1.79 ± 0.43]L, P 〈 0.05; [2.09±0.62] vs [1.64± 0.46]L, P〈 0.05; [1.35 ± 0.35] vs [0.92 ± 0.70]L, P〈 0.05）; while they did not differ significantly in the control group before and after treatment （P〈 0.05）. Conclusions The efficacy of acupoint injections of mycobacterium phlei F.U.36, huangqi and cordate houttuynia for stable asthma is better than that of conventional therapy.